Rhythm Pharmaceuticals
Stock Forecast, Prediction & Price Target
Rhythm Pharmaceuticals (RYTM) stock Price Target by analysts
$63.4
Potential downside: -34.80%
Rhythm Pharmaceuticals price prediction
What is Rhythm Pharmaceuticals stock analysts` prediction?
Rhythm Pharmaceuticals stock forecast: Based on 4 Wall Street analysts` predicted price targets for Rhythm Pharmaceuticals in the last 3 months, the avarage price target is $63.4, with a high forecast of $NaN. The average price target represents a -34.80% change from the last price of $97.25.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Rhythm Pharmaceuticals stock Price Target by analysts
Full breakdown of analysts given Rhythm Pharmaceuticals price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Corinne Jenkins Goldman Sachs | 50% 2/4 | 9 months ago | $66 -32.13% downside | $60.02 | StreetInsider | Previous targets (3) |
Corinne Jenkins Goldman Sachs | 50% 2/4 | 10 months ago | $59 -39.33% downside | $55.79 | StreetInsider | Previous targets (3) |
Alan Carr Needham | 0% 0/2 | 10 months ago | $64 -34.19% downside | $55.79 | StreetInsider | Previous targets (1) |
Raghuram Selvaraju H.C. Wainwright | 0% 0/1 | 12 months ago | $64 -34.19% downside | $53.17 | TheFly | Previous targets (0) |
Jonathan Wolleben JMP Securities | 0% 0/1 | 12 months ago | $64 -34.19% downside | $54 | StreetInsider | Previous targets (0) |
Alan Carr Needham | 0% 0/2 | about 1 year ago | $55 -43.44% downside | $49.61 | StreetInsider | Previous targets (1) |
Unknown Goldman Sachs | N/A | almost 3 years ago | $35 -64.01% downside | $24.68 | Benzinga | N/A |
Corinne Jenkins Goldman Sachs | 50% 2/4 | about 3 years ago | $28 -71.20% downside | $20.24 | TheFly | Previous targets (3) |
Corinne Jenkins Goldman Sachs | 50% 2/4 | about 3 years ago | $6 -93.83% downside | $6.38 | TheFly | Previous targets (3) |
Dae Gon Ha Stifel Nicolaus | 100% 1/1 | about 3 years ago | $25 -74.29% downside | $3.9 | TheFly | Previous targets (0) |
Rhythm Pharmaceuticals Financial Estimates
Rhythm Pharmaceuticals Revenue Estimates
Rhythm Pharmaceuticals EBITDA Estimates
Rhythm Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $3.15M N/A | $23.63M 649.46% | $77.42M 227.55% | Avg: $185.97M Low: $165.18M High: $219.58M avg. 140.19% | Avg: $354.34M Low: $311.56M High: $400.64M avg. 90.53% | Avg: $678.24M Low: $596.36M High: $766.87M avg. 91.40% | Avg: $1.02B Low: $898.55M High: $1.15B avg. 50.67% |
Net Income
% change YoY
| $-68.00M N/A | $-183.08M -169.20% | $-184.67M -0.87% | Avg: $-159.09M Low: $-212.81M High: $-89.39M avg. 13.85% | Avg: $-24.56M Low: $-72.66M High: $85.93M avg. 84.55% | Avg: $191.70M Low: $161.61M High: $224.26M avg. 880.34% | Avg: $391.48M Low: $330.04M High: $457.98M avg. 104.21% |
EBITDA
% change YoY
| $-170.05M N/A | $-175.91M -3.44% | $-168.46M 4.23% | Avg: $-37.19M Low: $-43.91M High: $-33.03M avg. 77.92% | Avg: $-70.86M Low: $-80.12M High: $-62.31M avg. -90.53% | Avg: $-135.64M Low: $-153.37M High: $-119.27M avg. -91.40% | Avg: $-204.38M Low: $-231.09M High: $-179.71M avg. -50.67% |
EPS
% change YoY
| -$1.37 N/A | -$3.51 -156.20% | -$3.2 8.83% | Avg: -$2.43 Low: -$3.69 High: -$1.55 avg. 24.02% | Avg: $0.02 Low: -$1.26 High: $1.49 avg. 100.89% | Avg: $3.32 Low: $2.8 High: $3.89 avg. 15239.17% | Avg: $6.79 Low: $5.72 High: $7.94 avg. 104.21% |
Operating Expenses
% change YoY
| $172.61M N/A | $200.66M 16.24% | $252.48M 25.82% | Avg: $1.08B Low: $962.23M High: $1.27B avg. 329.07% | Avg: $2.06B Low: $1.81B High: $2.33B avg. 90.53% | Avg: $3.95B Low: $3.47B High: $4.46B avg. 91.40% | Avg: $5.95B Low: $5.23B High: $6.73B avg. 50.67% |
FAQ
What is Rhythm Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 270.74% in 2025-2028.
We have gathered data from 8 analysts. Their low estimate is -212.81M, average is -159.09M and high is -89.39M.
What is Rhythm Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 93.20% in 2025-2028.
We have gathered data from 8 analysts. Their low revenue estimate is $165.18M, average is $185.97M and high is $219.58M.
What is Rhythm Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 3867.07% in 2025-2028.
We have gathered data from 8 analysts. Their low earnings per share estimate is -$3.69, average is -$2.43 and high is $-1.55.
What is the best performing analyst?
In the last twelve months 4 analysts have been covering Rhythm Pharmaceuticals stock. The most successful analyst is Corinne Jenkins whose win rate is 50%. He has correctly predicted 2/4 price targets.